By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Markets > Stocks > Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines
Stocks

Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines

News Room
Last updated: 2023/05/28 at 3:47 AM
By News Room
Share
3 Min Read
SHARE
2/2

© Reuters. FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron

2/2

By Blake Brittain

(Reuters) – Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc (NYSE:) and Moderna (NASDAQ:) Inc in Delaware federal court, again claiming that the companies’ COVID-19 vaccines infringe its patents.

The new lawsuits mark the third time Alnylam has sued Pfizer and Moderna in Delaware for allegedly violating its patent rights in lipid nanoparticle (LNP) technology, which the vaccines use to deliver genetic material into the body.

Alnylam is again seeking an unspecified share of royalties from the companies’ vaccine sales. Pfizer earned $37.8 billion from sales of its COVID-19 vaccine Comirnaty last year, while Moderna made $18.4 billion from its vaccine Spikevax.

Representatives for Alnylam, Moderna and Pfizer did not immediately respond to requests for comment on the new lawsuits. Moderna and Pfizer have denied the allegations in the earlier cases and argued that Alnylam’s patents are invalid.

Cambridge, Massachusetts-based Alnylam first sued Moderna and Pfizer last March. It filed another pair of complaints last July over an additional LNP patent, which were later consolidated with its earlier lawsuits.

The lawsuits filed Friday include four new infringement claims against Pfizer and three against Moderna.

The complaints are part of a wave of patent lawsuits filed by biotech companies over COVID-19 vaccines, including a case brought by Moderna against Pfizer last year in Massachusetts.

Alnylam told the Delaware court that it pioneered LNP technology “essential” to the mRNA-based vaccines more than a decade ago. It also said it gave Moderna confidential information about the technology in 2014 during discussions about a potential collaboration.

The cases are Alnylam Pharmaceuticals Inc v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:23-cv-00580 and Alnylam Pharmaceuticals Inc v. Pfizer Inc, U.S. District Court for the District of Delaware, No. 1:23-cv-00578.

For Alnylam: William Gaede, Sarah Columbia, Sarah Fischer, Ian Brooks and Bhanu Sadasivan of McDermott Will & Emery

For Moderna and Pfizer: attorney information not available

Read more:

Alnylam files patent infringement lawsuits against Pfizer, Moderna

Pfizer, Moderna COVID-19 vaccines infringe new Alnylam patent, lawsuits say

Pfizer says COVID-19 vaccine lawsuit is based on bogus patent

Read the full article here

News Room May 28, 2023 May 28, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
The power crunch threatening America’s AI ambitions

Many utility companies are pinning their short-term hopes on “demand response” solutions…

Why beef prices are out of control in the U.S.

Watch full video on YouTube

Stocks close lower to start the week, Stifel’s bullish Tesla call

Watch full video on YouTube

Touchstone Dynamic Large Cap Growth Fund Q3 2025 Commentary

At Touchstone Investments, we recognize that not all mutual fund companies are…

Israel stepping up ‘creeping annexation’ of West Bank, Palestinian PM says

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

CPS reports solid 2023 performance, eyes future growth By Investing.com

By News Room
Stocks

Niu Technologies faces mixed results in Q4 2023 By Investing.com

By News Room
Stocks

Exagen Inc. reports strong 2023 revenue growth By Investing.com

By News Room
Stocks

Legacy Housing reports mixed results amid sales decline By Investing.com

By News Room
Stocks

Harmony Biosciences exec sells over $383k in stock By Investing.com

By News Room
Stocks

Biofrontera posts record revenue and outlines growth plans By Investing.com

By News Room
Stocks

Granite Ridge CFO buys $31,000 in company stock By Investing.com

By News Room
Stocks

Coliseum Capital Management buys MasterCraft Boat shares worth over $3.2m By Investing.com

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?